原癌基因酪氨酸蛋白激酶Src
药物发现
酪氨酸激酶
激酶
受体酪氨酸激酶
机制(生物学)
化学
癌症研究
信号转导
细胞生物学
生物
生物化学
哲学
认识论
作者
Xia-Wen Dang,Ji-Long Duan,Emily Ye,Nian-Dong Mao,Renren Bai,Xinglu Zhou,Xiang‐Yang Ye
标识
DOI:10.1016/j.bioorg.2023.106934
摘要
Proto-oncogene tyrosine-protein kinase Src, also known as c-Src, belongs to the family of non-receptor tyrosine protein kinases (TKs) called Src kinases. It plays a crucial role in cell division, motility, adhesion, and survival in both normal cells and cancer cells by activating various signaling pathways mediated by multiple cytokines. Additionally, c-Src kinase has been implicated in osteoclasts and bone loss diseases mediated by inflammation and osteoporosis. In recent years, remarkable advancements have been achieved in the development of c-Src inhibitors, with several candidates progressing to the clinical stage. This review focuses on the research progress in several areas, including the mechanism of action, drug discovery, combination therapy, and clinical research. By presenting this information, we aim to provide researchers with convenient access to valuable insights and inspire new ideas to expedite future drug discovery programs.
科研通智能强力驱动
Strongly Powered by AbleSci AI